Press Releases - 2023-09-12

Date	Title	Company
12-Sep-2023	Septerna Announces Novel GPCR-targeted Program Acquired by Vertex	Businesswire
12-Sep-2023	ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease	Businesswire
12-Sep-2023	2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies	Businesswire
12-Sep-2023	BRAIN Biotech AG: Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family	BRAIN Biotech AG
12-Sep-2023	Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases	Businesswire
12-Sep-2023	Freudenberg Medical Innovates with Advanced Hypotube Coating Automation	Businesswire
12-Sep-2023	Brainify.AI Joins Johnson & Johnson Innovation JLABS	Newswire
12-Sep-2023	United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report	Businesswire
12-Sep-2023	OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs	Businesswire
12-Sep-2023	Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer	Businesswire
12-Sep-2023	Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute	Businesswire
12-Sep-2023	CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage	CureVac
12-Sep-2023	Newest Release of Titian Software’s Mosaic Sample Management Platform Enhances Sample Logistics	Businesswire
12-Sep-2023	Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer	Bristol Myers Squibb
12-Sep-2023	Cingulate Announces Pricing of $4.0 Million Public Offering	Cingulate
12-Sep-2023	RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3	Businesswire
12-Sep-2023	Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)	AstraZeneca
12-Sep-2023	HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer	HUTCHMED
12-Sep-2023	Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections	The Global Antibiotic Research & Development Partnership (GARDP) / Orchid Pharma Ltd (Orchid)
12-Sep-2023	MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies	Businesswire